Key development
According to an August 13, 2026 Form 13F filing, Berkshire Hathaway (BRK.B) initiated a modest stake in DR Horton (DHI) while simultaneously completing a $6.8 billion homebuilder acquisition at $72.50 per share that closed on July 24, 2026. The activity, executed under new CEO Greg Abel, represents Berkshire’s first quarter as a net stock buyer in 15 quarters and signals a return to deploying cash after a prolonged pause.
Market context and sentiment
The timing of Berkshire’s moves arrives amid subdued housing sentiment. The NAHB Housing Market Index remains at 35 - its 16th consecutive month below 40 - while mortgage rates are above 6.8%, complicating buyer affordability. Survey data from BTIG showed July sales falling as site traffic failed to translate into closings. Taken together, these indicators highlight why the sector is out of favor and why Berkshire’s actions read as contrarian positioning for a future cycle shift.
DR Horton’s recent performance
DR Horton shares trade at $148.34 and the company carries a trailing price-to-earnings multiple of 13.6x. Over the past two years, revenue declined from $36.8 billion in fiscal 2024 to $34.25 billion in fiscal 2025, a drop of 7.2%. Earnings per share fell from $14.34 to $11.57, a 19.3% decline. Gross margin has compressed from 25.1% to 22.5%, a reduction of 260 basis points, which the company has absorbed in part by offering incentives to move inventory in a high-rate environment.
Balance sheet and valuation snapshot
Other reported metrics include a market capitalization of $41.62 billion, return on equity of 14.5%, and a debt-to-equity ratio of 30.2%. DR Horton pays a small dividend with a yield of 1.2% and displays a beta of 1.38, indicating it will likely amplify moves in a housing recovery. External valuations cited in the reporting show Wells Fargo assigning a $155 price target with an Equal Weight rating, while InvestingPro’s fair value estimate stands at $153.73, implying a modest 3.6% upside from current levels.
Scale advantages and sector dynamics
Proponents of DR Horton point to its scale as a competitive advantage. As the largest U.S. homebuilder by closings, the company may have greater pricing power, more flexible land option approaches, and operational efficiencies compared with smaller peers. The 14.5% ROE is presented as respectable for a cyclical enterprise and suggests DR Horton retains financial strength even as margins compress.
Industry headwinds and performance dispersion
The wider homebuilding sector is under pressure. Mortgage rates above 6.8%, extended low builder sentiment and industry-wide margin contraction present headwinds. Smaller builders illustrate the profitability strain - for example, Smith Douglas Homes reported a 91% EPS miss despite 22% revenue growth, underscoring that top-line expansion has not translated to consistent earnings across the sector.
Interpretation of Berkshire’s strategy
Berkshire’s concurrent small stake in DR Horton and acquisition of a homebuilder for $6.8 billion suggests a multi-angle exposure to the housing cycle: the acquisition provides immediate scale exposure, while the DHI stake offers optionality if conditions improve. The filing and related commentary frame these actions as positioning for a 2027-2028 recovery in housing activity should mortgage rates and conditions normalize and demand remain intact.
Risks highlighted
The main risks flagged include the possibility that interest rates remain elevated for an extended period and geopolitical developments that could lift oil prices above $90 - as occurred in August - thereby increasing construction costs and further pressuring buyer demand. Additionally, prolonged weak builder sentiment, which has persisted below 40 for 16 months, remains a constraint on a near-term recovery.
Note: This article summarizes the positions, financial metrics and market context reported in filings and market data.